- Advanced search
|International Nonproprietary Names|
|Search PubMed clinical trials||simtuzumab|
|Search PubMed titles||simtuzumab|
|Search PubMed titles/abstracts||simtuzumab|
|Simtuzumab is an investigational monoclonal antibody targeting lysyl oxidase-like 2 (LOXL2). The antibody is reported to be an allosteric modulator of LOXL2 enzymatic activity [6-7].
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. Peptide sequence matches reveal that US8461303 is the covering patent . The heavy chain variable domain sequence of simtuzumab (from IMGT) matches the sequence for the AB0023 M20 variant 3 clone in US8461303.